These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial. Platzbecker U; Wong RS; Verma A; Abboud C; Araujo S; Chiou TJ; Feigert J; Yeh SP; Götze K; Gorin NC; Greenberg P; Kambhampati S; Kim YJ; Lee JH; Lyons R; Ruggeri M; Santini V; Cheng G; Jang JH; Chen CY; Johnson B; Bennett J; Mannino F; Kamel YM; Stone N; Dougherty S; Chan G; Giagounidis A Lancet Haematol; 2015 Oct; 2(10):e417-26. PubMed ID: 26686043 [TBL] [Abstract][Full Text] [Related]
7. [Myelodysplastic syndromes or refractory anemias]. Fenaux P Rev Prat; 1993 Jun; 43(11):1379-85. PubMed ID: 8235387 [TBL] [Abstract][Full Text] [Related]
8. Myelodysplastic syndromes: from morphology to molecular biology. Part I. Classification, natural history and cell biology of myelodysplasia. Yoshida Y; Stephenson J; Mufti GJ Int J Hematol; 1993 Apr; 57(2):87-97. PubMed ID: 8494998 [TBL] [Abstract][Full Text] [Related]
9. Chromosomal studies after bone marrow transplantation for leukaemia in children. van den Berg H; Beverstock G; Westerhof JP; Vossen JM Bone Marrow Transplant; 1991 May; 7(5):335-42. PubMed ID: 2070142 [TBL] [Abstract][Full Text] [Related]
10. Bone marrow mononuclear cell telomere length in acute myeloid leukaemia and high-risk myelodysplastic syndrome. Warny M; Helby J; Sengeløv H; Nordestgaard BG; Birgens H; Bojesen SE Eur J Haematol; 2019 Mar; 102(3):218-226. PubMed ID: 30427547 [TBL] [Abstract][Full Text] [Related]
12. Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation. Koenecke C; Göhring G; de Wreede LC; van Biezen A; Scheid C; Volin L; Maertens J; Finke J; Schaap N; Robin M; Passweg J; Cornelissen J; Beelen D; Heuser M; de Witte T; Kröger N; Haematologica; 2015 Mar; 100(3):400-8. PubMed ID: 25552702 [TBL] [Abstract][Full Text] [Related]
13. [Myelodysplastic syndromes--pathogenesis and treatment]. Homenda W; Pejska M; Kochanowska-Demczyna A Wiad Lek; 2005; 58(3-4):204-7. PubMed ID: 16119165 [TBL] [Abstract][Full Text] [Related]
14. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management. Garcia-Manero G Am J Hematol; 2015 Sep; 90(9):831-41. PubMed ID: 26294090 [TBL] [Abstract][Full Text] [Related]
15. When to treat myelodysplastic syndromes. Akhtari M Oncology (Williston Park); 2011 May; 25(6):480-6. PubMed ID: 21717901 [TBL] [Abstract][Full Text] [Related]